HKSE - Delayed Quote HKD
Zhaoke Ophthalmology Limited (6622.HK)
1.720
-0.020
(-1.15%)
As of 11:48:10 AM GMT+8. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
57,215
18,750
--
--
--
Cost of Revenue
10,282
4,503
--
--
--
Gross Profit
46,933
14,247
--
--
--
Operating Expense
344,767
466,259
405,550
396,388
118,323
Operating Income
-297,834
-452,012
-405,550
-396,388
-118,323
Net Non Operating Interest Income Expense
68,301
69,478
27,273
3,087
927
Pretax Income
-227,052
-384,488
-407,317
-2,129,780
-726,981
Tax Provision
10
550
--
--
--
Net Income Common Stockholders
-227,062
-385,038
-407,317
-2,129,780
-726,981
Diluted NI Available to Com Stockholders
-227,062
-385,038
-407,317
-2,129,780
-726,981
Basic EPS
-0.42
-0.71
-0.75
-5.16
-1.36
Diluted EPS
-0.42
-0.71
-0.75
-5.16
-1.36
Basic Average Shares
545,070.297
543,922.707
542,172.689
412,383.886
535,155.500
Diluted Average Shares
545,070.297
543,922.707
542,172.689
412,383.886
535,155.500
Total Operating Income as Reported
--
-376,567
-404,175
-364,332
-55,348
Total Expenses
355,049
470,762
405,550
396,388
118,323
Net Income from Continuing & Discontinued Operation
-227,062
-385,038
-407,317
-2,129,780
-726,981
Normalized Income
-227,388.250
-385,364.250
-407,861
-2,143,384
-727,247
Interest Income
--
77,399
30,415
5,036
2,582
Interest Expense
9,098
7,921
3,142
1,949
1,655
Net Interest Income
68,301
69,478
27,273
3,087
927
EBIT
-217,954
-376,567
-404,175
-2,127,831
-725,326
EBITDA
-217,954
-327,863
-369,101
-2,102,000
-705,473
Reconciled Cost of Revenue
10,282
4,503
--
--
--
Reconciled Depreciation
--
48,704
35,074
25,831
19,853
Net Income from Continuing Operation Net Minority Interest
-227,062
-385,038
-407,317
-2,129,780
-726,981
Total Unusual Items Excluding Goodwill
435
435
544
13,604
266
Total Unusual Items
435
435
544
13,604
266
Normalized EBITDA
-218,389
-328,298
-369,645
-2,115,604
-705,739
Tax Rate for Calcs
0
0
--
--
--
Tax Effect of Unusual Items
108.750
108.750
--
--
--
12/31/2020 - 4/29/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2509.HK Qyuns Therapeutics Co., Ltd.
11.000
+0.36%
3759.HK Pharmaron Beijing Co., Ltd.
13.640
-0.29%
1477.HK OCUMENSION-B
5.450
-1.27%
6821.HK Asymchem Laboratories (Tianjin) Co., Ltd.
51.050
+0.79%
2171.HK CARsgen Therapeutics Holdings Limited
15.000
-2.60%
1541.HK IMMUNEONCO-B
6.660
-5.93%
1548.HK GENSCRIPT BIO
11.240
+1.63%
1672.HK ASCLETIS-B
6.130
-2.39%
2269.HK WuXi Biologics (Cayman) Inc.
22.900
+0.44%
1733.TW Apex Biotechnology Corp.
32.15
+0.31%